---
title: "Hinova Pharmaceuticals Inc. (688302.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688302.SH.md"
symbol: "688302.SH"
name: "Hinova Pharmaceuticals Inc."
industry: "Pharmaceuticals"
---

# Hinova Pharmaceuticals Inc. (688302.SH)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | CN Market |
| Website | [www.hinovapharma.com](https://www.hinovapharma.com) |

## Company Profile

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-15T04:30:09.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 153 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21414.67% |  |
| Net Profit YoY | 31.22% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 4.06 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.47B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 23.61M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -12.40% | D |
| Profit Margin | -612.36% | E |
| Gross Margin | 99.62% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21414.67% | A |
| Net Profit YoY | 31.22% | B |
| Total Assets YoY | -2.96% | D |
| Net Assets YoY | -10.61% | D |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -16.33% | D |
| OCF YoY | 21414.67% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.02 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 19.24% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Hinova Pharmaceuticals Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-12.40%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-612.36%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "99.62%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21414.67%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "31.22%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.96%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-10.61%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-16.33%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "21414.67%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "19.24%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Allist (SH.688578) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A |
| 03 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B |
| 05 | Salubris (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -30.89 | 194/222 | - | - | - |
| PB | 4.06 | 169/222 | 4.75 | 4.33 | 3.33 |
| PS (TTM) | 189.15 | 221/222 | 15585.05 | 487.03 | 212.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-09T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 50% |
| Overweight | 1 | 50% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 45.10 |
| Highest Target | 80.00 |
| Lowest Target | 80.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/688302.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688302.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688302.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.